Latest Headlines

Latest Headlines

Pfizer widens Xalkori's reach with another targeted lung cancer approval

Pfizer's Xalkori was already approved to treat metastatic non-small cell lung cancer patients with ALK-positive tumors. But now, the company has a new selling point for the med.

Roche challenges hometown rival Novartis with new targeted lung-cancer med Alecensa

As of Friday, Roche has a new FDA approval in hand for lung cancer treatment Alecensa--and with it, it's about to go head-to-head with its crosstown rival.

Cheap Dx spots lung cancer mutation ripe for Pfizer drug

Personalized medicine takes another step forward, as scientists from Pfizer and South Korea make progress developing a diagnostic test that can quickly and cheaply identify patients who can benefit from the company's lung cancer drug Xalkori (crizotinib).